Log in to search using one of your social media accounts:


Preclinical Evaluation of the Stability, Safety and Efficacy of CD101, a Novel Echinocandin

Fungal infections pose a significant public health burden with high morbidity and mortality. CD101 is a novel echinocandin under development for the treatment and prevention of systemic Candida infections. Preclinical studies were conducted to evaluate the metabolic stability, plasma protein binding, pharmacokinetics, toxicity, and efficacy of CD101 at various dose levels. CD101 was stable to biotransformation in rat/monkey/human liver microsomes and rat/monkey/dog/human hepatocytes.
Source: The Aspergillus Website - updates - Category: Respiratory Medicine Authors: Source Type: news

Related Links:

More News: Aspergillus | Candida | Fungal Infections | International Medicine & Public Health | Liver | Respiratory Medicine | Study | Toxicology | Urology & Nephrology | Websites